

Getting started with TAZVERIK® (tazemetostat)

INDICATION What is TAZVERIK?

TAZVERIK is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TAZVERIK? TAZVERIK can cause serious side effects, including:

Risk of new cancers. An increase in new (second) cancers has happened
in people who were treated with TAZVERIK. Talk with your healthcare
provider about your risk of developing new cancers. Your healthcare provider
will monitor you for new cancers after your treatment with TAZVERIK.
Tell your healthcare provider if you are more tired than usual, or have easy
bruising, fever, bone pain, or paleness.

Your guide to treatment with TAZVERIK® (tazemetostat)

Your doctor may have prescribed or recommended TAZVERIK® to help treat your epithelioid sarcoma. You may find it helpful for you and those involved in your care to learn more about your treatment and what to expect while taking TAZVERIK.

The information in this brochure is not meant to take the place of talking with your healthcare team. Always talk with your doctor if you have any questions about your treamtment or side effects.

Table of contents:

| Page 3 | What should I know about epithelioid sarcoma? |
|--------|--|
| Page 4 | What is TAZVERIK and how does it work? |
| Page 5 | What were the study results and side effects from the TAZVERIK clinical study? |
| Page 6 | What important information should I know before and while taking TAZVERIK? |
| Page 7 | How do I take TAZVERIK? |
| Page 8 | Ipsen Cares patient support program offerings |
| Page 9 | Notes |

IMPORTANT SAFETY INFORMATION (continued)

Pages 10 & 11 Important Safety Information and Indication

Before taking TAZVERIK, tell your healthcare provider if you are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Females who are able to become pregnant should use effective non-hormonal birth control during treatment and for 6 months after the final dose of TAZVERIK. Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.

Please see additional Important Safety Information on pages 10-11 and full Prescribing Information, including Medication Guide.


What should I know about epithelioid sarcoma?

There is a lot to know about epithelioid sarcoma, and you might be feeling overwhelmed. Here are some basic facts to help you get a better understanding of what epithelioid sarcoma is.

Epithelioid sarcoma is a rare type of soft tissue cancer. It most often starts as a hard, sometimes painless lump in tissues under the skin of a finger, hand, or forearm, though it can start in other areas of the body as well. Sometimes, epithelioid sarcoma appears as skin ulcers that do not heal. These could look like open wounds over the growths. Epithelioid sarcoma can spread to other parts of the body.

There are two types of epithelioid sarcoma:

- Distal-type: The more typical form that often occurs away from the center of the body.
- Proximal-type: A rare form that tends to be more aggressive and occurs near the center of the body.



Working with a healthcare professional who specializes in treating soft tissue sarcomas may give you a better understanding of your disease. Talk with your doctor about the right treatment option for you.



What is TAZVERIK® and how does it work?

TAZVERIK® is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

TAZVERIK is an oral, twice-daily treatment that works differently from other cancer treatments

- TAZVERIK is not a chemotherapy treatment and does not kill cancer cells directly.
- A protein called EZH2 is found in many cells in the body. When there is increased activity, it can lead to tumor growth. TAZVERIK is the first type of therapy that was designed to target and block EZH2.



What is the most important information I should know about TAZVERIK?

TAZVERIK can cause serious side effects, including:

• Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

Please see additional Important Safety Information on pages 10-11 and full Prescribing Information, including Medication Guide.

What were the study results and side effects from the TAZVERIK clinical study?

What were the results of the study?

In cancer treatment studies, researchers want to know how many patients respond to therapy. This is measured as overall response, or the percentage of patients whose tumors either shrank by at least 30% or completely disappeared. Every individual is different and may respond differently.

TAZVERIK was studied in a clinical trial of 62 patients with epithelioid sarcoma that had spread or grown and could not be removed by surgery:

of patients (n=9/62) had an overall response* † to TAZVERIK (meaning the target tumor(s) either reduced in size by at least 30% or completely disappeared)

of patients (n=1/62) had a complete response (meaning their target tumors completely disappeared)

7 % of patients (n=8/62) had a partial response (meaning their target tumors reduced in size by at least 30%)

of patients who responded (complete or partial response) experienced a response lasting at least 6 months (length of responses ranged from 3.7 to more than 24 months)

*The time to tumor shrinkage in the clinical trial ranged from around 1 month to around 18 months.

[†]The overall response is the sum of partial responses and complete responses. It means the tumor either reduced in size by at least 30% or completely disappeared.

What are the possible side effects of TAZVERIK?

It is important that you are informed about the potential side effects during treatment with TAZVERIK. Talk to your doctor about concerns you may have.

The most common side effects of TAZVERIK in people with epithelioid sarcoma include:

Pain

Nausea

Vomiting

Tiredness

Decreased appetite

Constipation

These are not all the possible side effects of TAZVERIK. Tell your healthcare provider right away if you have any side effect that bothers you or that does not go away.

You are encouraged to report side effects of prescription drugs to Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.



What important information should I know before and while taking TAZVERIK®?

Before taking TAZVERIK®, tell your healthcare provider about all your medical conditions, including if you:

 Are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.



• Females who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.



- Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.
- Are breastfeeding or plan to breastfeed. It is not known if TAZVERIK
 passes into your breast milk. Do not breastfeed during treatment and for
 I week after the final dose of TAZVERIK.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.

What should I avoid while taking TAZVERIK®?

- Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.
- Avoid taking St. John's wort during treatment with TAZVERIK.

How do I take TAZVERIK?

Your doctor will decide whether TAZVERIK may be a treatment option for you. Always follow your doctor's instructions about how to take TAZVERIK.

What is the recommended dose?

The recommended dosing is 4 tablets (200 mg each) twice daily. Your doctor will confirm what your dose should be, as some patients may need a different dose.









How to take TAZVERIK



Take TAZVERIK exactly as your healthcare provider tells you.

Take TAZVERIK 2 times each day.

Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with TAZVERIK if you get certain side effects.



You can take TAZVERIK with or without food.





Each tablet should be swallowed whole. Do not cut, crush, or chew TAZVERIK tablets.



If you miss a dose or vomit after taking your dose, just skip that dose and take the next dose at your regular time.

It is important to keep your doctor informed of any changes during your treatment and to follow your treatment regimen as instructed.

Please see additional Important Safety Information on pages 10-11 and full <u>Prescribing Information</u>, including Medication Guide.



6

Ipsen Cares Patient Support Program Offerings

To help facilitate access to TAZVERIK® (tazemetostat) for patients with a valid prescription, the Ipsen Cares patient support program offerings can help you understand your insurance coverage and identify any financial or product support that may be available to you. Below is a list of support programs for which you may be eligible:



Patient Assistance Program (PAP)

Patients may be eligible to receive a limited supply of free medication if they are uninsured or underinsured (based on program eligibility criteria).



Quick Start Program

New commercial patients may be eligible to receive a limited supply of free medication.



Bridge Supply Program

Helping existing commercial patients access medication should they experience change or delay in drug coverage.



Co-Pay Assistance Program


Patients with commercial health insurance may be eligible to receive co-payment assistance from Ipsen to help reduce out-of-pocket costs for TAZVERIK.*



If you are interested in learning more about any of the support offerings mentioned, including eligibility requirements, visit <u>ipsencares.com</u> or contact Ipsen Cares at 1-866-435-5677, Monday through Friday (8 AM – 8 PM ET).

Note: All patient support is subject to eligibility criteria and program terms and conditions.

*This offer is not valid for cash-paying patients or patients currently enrolled in Medicare, Medicaid, or any other federal or state healthcare program. Limitations apply. Void where prohibited.



Tip: Use this page to list any questions for your healthcare team.



IMPORTANT SAFETY INFORMATION AND INDICATION

What is the most important information I should know about TAZVERIK® (tazemetostat)?

TAZVERIK can cause serious side effects, including:

• Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.
- **Females** who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.
- Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.
- are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.

What should I avoid while taking TAZVERIK?

- Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.
- · Avoid taking St. John's wort during treatment with TAZVERIK.

Talk to your healthcare provider before starting any new medications, vitamins, or herbal supplements.

What are the possible side effects of TAZVERIK?

The most common side effects of TAZVERIK in people with epithelioid sarcoma include:

- · Pain
- Tiredness
- Nausea
- · Decreased appetite
- Vomiting
- Constipation

These are not all the possible side effects of TAZVERIK.

Call your doctor for medical advice about side effects. You may report side effects to Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION What is TAZVERIK?

TAZVERIK is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

Please see the full Prescribing Information, including Medication Guide.



11

WHAT IS TAZVERIK® (tazemetostat)?

TAZVERIK® is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about TAZVERIK? TAZVERIK can cause serious side effects, including:

• Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

Please see additional Important Safety Information on pages 10-11 and full Prescribing Information, including Medication Guide.

- TAZVERIK is the **first and only** FDA-approved therapy specifically studied in epithelioid sarcoma patients.
 - Studied in the largest, global trial for epithelioid sarcoma patients (N=62).
- $\boldsymbol{\cdot}$ It is an \boldsymbol{oral} $\boldsymbol{medication},$ taken twice daily with or without food.
- Financial assistance or other patient support programs may be available to eligible patients through Ipsen Cares.

Ongoing Support from Ipsen Cares

If you are interested in learning more about any of the support offerings mentioned, including eligibility requirements, visit <u>ipsencares.com</u> or contact lpsen Cares at 1-866-435-5677, Monday through Friday (8 AM – 8 PM ET).

TAZVERIK is a registered trademark of Epizyme, Inc., an Ipsen company. IPSEN CARES is a registered trademark of Ipsen S.A. ©2023 Ipsen Biopharmaceuticals, Inc. All rights reserved. TAZ-US-000463 11/2023

